Since 2005, vagus nerve stimulation (VNS) therapy has been approved by the Food and Drug Administration (FDA) as a safe and effective treatment option for treatment resistant depression. It has been tested in several research studies, including one at Keck Medical Center of USC with Carlos Figueroa, MD, a psychiatrist with Keck Medicine of USC and a clinical assistant professor in the Keck School of Medicine of USC’s Department of Psychiatry and Behavioral Sciences.

As of March 31, Figueroa is leading the first clinical trial study in Los Angeles at Keck Medical Center to provide additional evidence of the benefits of VNS therapy for patients with treatment resistant depression. This trial, called the RECOVER study, is approved by Medicare and in partnership with nearly 100 other leading hospitals and medical centers across the United States.

To continue reading this story, click here.